High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

This study tests whether a higher dose of furmonertinib — a targeted therapy that crosses into the brain — works better than the standard dose for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has spread to the brain. **You may be eligible if...** - You have advanced or metastatic non-small cell lung cancer - Your cancer has an EGFR mutation (a specific genetic change) - Your cancer has spread to the brain - You have not previously been treated with an EGFR inhibitor, OR you have progressed on a first or second-generation EGFR inhibitor **You may NOT be eligible if...** - You have previously received a third-generation EGFR inhibitor (like osimertinib) - Your brain metastases require immediate surgery or high-dose steroids - You have serious heart problems (QT prolongation or weak heart function) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.